- Exchange: ASE
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for Avexa Ltd (AVX)
| Open: | - | Day's Range: | - | Volume: | 645,335 |
|---|---|---|---|---|---|
| Previous Close: | 0.0170 | 52wk Range: | 0.0150 - 0.0340 | 1-Yr Rtn: | -29.17% |
Key Statistics for AVX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(06/2013) | - |
| Relative P/E vs. AS51 | - |
| Earnings Per Share (ttm) | -0.0043 |
| Est. EPS (06/2013) | - |
| Est. PEG Ratio | - |
| Market Cap (M AUD) | 14.41 |
| Shares Outstanding (M) | 847.69 |
| 30 Day Average Volume | 463,084 |
| Price/Book (mrq) | 0.8462 |
| Price/Sale (ttm) | 62.1151 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/26/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for AVX
Company Profile & Key Executives for AVX
Avexa Limited is a pharmaceutical company focused on the research and development of anti-infective drugs for such diseases as HIV, Hepatitis B, and vancomycin resistant bacterial infections.
| Jonathan A V CoatesInterim CEO/Chief Scientific Ofcr | Lee MitchellSecretary |
| M KlapakisController |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
AVX News
-
Industry News
Advertisement
- 1
- 2
- 3
- 4
- 5
Advertisement
Sponsored Links
Advertisements
Rate this Page